Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Affimed N.V. (AFMD : NSDQ)
 
 • Company Description   
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.

Number of Employees: 197

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.28 Daily Weekly Monthly
20 Day Moving Average: 1,719,413 shares
Shares Outstanding: 123.42 (millions)
Market Capitalization: $404.82 (millions)
Beta: 2.49
52 Week High: $9.82
52 Week Low: $2.88
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -16.96% -9.01%
12 Week -22.27% -15.66%
Year To Date -40.58% -29.34%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
TECHNOLOGIEPARK IM NEUENHEIMER FELD 582
-
HEIDELBERG,2M 69120
DEU
ph: 49-62-2167-4360
fax: 49-6221-653-0777
ir@affimed.com http://www.affimed.com
 
 • General Corporate Information   
Officers
Adi Hoess - Chief Executive Officer
Wolfgang Fischer - Chief Operating Officer
Angus Smith - Chief Financial Officer
Thomas Hecht - Director
Bernhard R.M. Ehmer - Director

Peer Information
Affimed N.V. (CORR.)
Affimed N.V. (RSPI)
Affimed N.V. (CGXP)
Affimed N.V. (BGEN)
Affimed N.V. (GTBP)
Affimed N.V. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: N01045108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 07/07/22
Share - Related Items
Shares Outstanding: 123.42
Most Recent Split Date: (:1)
Beta: 2.49
Market Capitalization: $404.82 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.21 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.79 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/07/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.52
Price/Cash Flow: -
Price / Sales: 8.47
EPS Growth
vs. Year Ago Period: -10.00%
vs. Previous Quarter: -29.41%
Sales Growth
vs. Year Ago Period: 1.71%
vs. Previous Quarter: 15.76%
ROE
03/31/22 - -
12/31/21 - -40.66
09/30/21 - -40.23
ROA
03/31/22 - -
12/31/21 - -24.86
09/30/21 - -23.18
Current Ratio
03/31/22 - -
12/31/21 - 3.20
09/30/21 - 3.07
Quick Ratio
03/31/22 - -
12/31/21 - 3.19
09/30/21 - 3.06
Operating Margin
03/31/22 - -
12/31/21 - -149.76
09/30/21 - -132.18
Net Margin
03/31/22 - -
12/31/21 - -149.76
09/30/21 - -132.18
Pre-Tax Margin
03/31/22 - -
12/31/21 - -142.50
09/30/21 - -123.37
Book Value
03/31/22 - -
12/31/21 - 1.64
09/30/21 - 1.61
Inventory Turnover
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.13
09/30/21 - 0.08
Debt-to-Capital
03/31/22 - -
12/31/21 - 11.15
09/30/21 - 7.00
 

Powered by Zacks Investment Research ©